Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829355 | 0.85 | CYP19A1 (0.50) | CYP3A4CYP1A2LMNACYP11B1CYP11B2 | |
| SCHEMBL29138449 | 0.81 | CYP19A1 (0.50) | CYP3A4CYP1A2LMNACYP11B1CYP11B2 | |
| SCHEMBL30048933 | 0.81 | CYP19A1 (0.50) | CYP3A4CYP1A2LMNACYP11B1CYP11B2 | |
| SCHEMBL6090239 | 0.81 | CYP19A1 (0.49) | CYP3A4CYP1A2LMNACYP11B1CYP11B2 | |
| SCHEMBL17974816 | 0.80 | KCNA5 (0.47) | CYP3A4CYP1A2LMNACYP11B1CYP11B2 | |
| SCHEMBL2423712 | 0.78 | CYP19A1 (0.55) | CYP3A4CYP1A2LMNACYP11B1CYP11B2 | |
| SCHEMBL9547408 | 0.78 | CYP19A1 (0.55) | CYP3A4CYP1A2LMNACYP11B1CYP11B2 | |
| SCHEMBL3021832 | 0.78 | CYP19A1 (0.55) | CYP3A4CYP1A2LMNACYP11B1CYP11B2 | |
| SCHEMBL1375896 | 0.78 | CYP19A1 (0.55) | CYP3A4CYP1A2LMNACYP11B1CYP11B2 | |
| SCHEMBL29896215 | 0.78 | CYP19A1 (0.55) | CYP3A4CYP1A2LMNACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108291307-B | Plating bath composition and method for electroless plating of palladium | 埃托特克德国有限公司 | 2020-02-14 | — | — | CN | claimed |
| US-10513780-B2 | Plating bath composition and method for electroless plating of palladium | ATOTECH DEUTSCHLAND GMBH (DE) | 2019-12-24 | — | — | US | claimed |
| EP-3380649-B1 | PLATING BATH COMPOSITION AND METHOD FOR ELECTROLESS PLATING OF PALLADIUM | ATOTECH DEUTSCHLAND GMBH (DE) | 2019-10-30 | — | — | EP | claimed |
| US-20180340260-A1 | PLATING BATH COMPOSITION AND METHOD FOR ELECTROLESS PLATING OF PALLADIUM | ATOTECH DEUTSCHLAND GMBH & CO. KG (F/K/A ATOTECH DEUTSCHLAND GMBH) (DE) | 2018-11-29 | — | — | US | claimed |
| EP-3380649-A1 | PLATING BATH COMPOSITION AND METHOD FOR ELECTROLESS PLATING OF PALLADIUM | ATOTECH Deutschland GmbH (DE) | 2018-10-03 | — | — | EP | claimed |
| CN-111138422-B | Medicine for preventing and treating lupus erythematosus and preparation method thereof | 牡丹江医学院 | 2020-11-17 | — | — | CN | disclosed |
| CN-111138422-A | Medicine for preventing and treating lupus erythematosus and preparation method thereof | 牡丹江医学院 | 2020-05-12 | — | — | CN | disclosed |
| CN-108291307-B | Plating bath composition and method for electroless plating of palladium | 埃托特克德国有限公司 | 2020-02-14 | — | — | CN | disclosed |
| US-10513780-B2 | Plating bath composition and method for electroless plating of palladium | ATOTECH DEUTSCHLAND GMBH (DE) | 2019-12-24 | — | — | US | disclosed |
| EP-3380649-B1 | PLATING BATH COMPOSITION AND METHOD FOR ELECTROLESS PLATING OF PALLADIUM | ATOTECH DEUTSCHLAND GMBH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-20180340260-A1 | PLATING BATH COMPOSITION AND METHOD FOR ELECTROLESS PLATING OF PALLADIUM | ATOTECH DEUTSCHLAND GMBH & CO. KG (F/K/A ATOTECH DEUTSCHLAND GMBH) (DE) | 2018-11-29 | — | — | US | disclosed |
| EP-3380649-A1 | PLATING BATH COMPOSITION AND METHOD FOR ELECTROLESS PLATING OF PALLADIUM | ATOTECH Deutschland GmbH (DE) | 2018-10-03 | — | — | EP | disclosed |
| US-9284323-B2 | Naphthalene acetic acid derivatives against HIV infection | GILEAD SCIENCES, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2013103738-A1 | NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | NFATC1, ACIN1, NAAA | CYP3A4 1722/4885CYP1A2 1211/4885LMNA 2505/4885 |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | CYP3A4 2161/4885CYP1A2 1383/4885LMNA 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.